1.	Sequential Vaccinations in Prostate Cancer Patients Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 030176, 03-C-0176, NCI-03-C-0176, NCI-5911, 5911, NCT00062153, NCT00060528
2.	Phase II Randomized Study of Vaccinia-PSA-TRICOM Vaccine, Fowlpox-PSA-TRICOM Vaccine, and Sargramostim (GM-CSF) Versus Empty Vector Control in Patients With Metastatic Androgen-Independent Prostate Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0309014, THERION-TBC-PRO-002, NCT00078585
3.	Vaccine Therapy and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Treating Patients With Prostate Cancer That Progressed After Surgery and/or Radiation Therapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-03075, U10CA021115, E9802, CDR0000422430, ECOG-E9802, NCT00108732
4.	153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 070106, 07-C-0106, NCI-07-C-0106, 7678, NCT00450619
5.	Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02048, E1809, U10CA021115, ECOG-E1809, NCT01145508
6.	Phase I Pilot Study of Vaccine Therapy Comprising Priming Vaccinations of Vaccinia-PSA-TRICOM and Recombinant Fowlpox GM-CSF (rF-GM-CSF) Followed By Boosting Vaccinations of Fowlpox-PSA-TRICOM With or Without rF-GM-CSF in Patients With Progressive or Locally Recurrent Prostate Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-05-C-0017, NCI-6066, 6066, NCT00098449
7.	Phase I Study of Vaccine Therapy Comprising Vaccinia-PSA-TRICOM Vaccine and Fowlpox-PSA-TRICOM Vaccine in Combination With Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody Ipilimumab (MDX-010) and Sargramostim (GM-CSF) in Patients With Androgen-Independent Metastatic Prostate Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-05-C-0167, 7207, NCI-7207, NCT00124670